NAMPT protects against 6-hydroxydopamine-induced neurotoxicity in PC12 cells through modulating SIRT1 activity

Zou,Xiao‑Dong; Guo,Shao‑Qing; Hu,Zhi‑Wei; Li,Wei‑Lang

doi:10.3892/mmr.2016.5034

NAMPT protects against 6-hydroxydopamine-induced neurotoxicity in PC12 cells through modulating SIRT1 activity

Authors:
- Xiao‑Dong Zou
- Shao‑Qing Guo
- Zhi‑Wei Hu
- Wei‑Lang Li
View Affiliations

Affiliations: Department of Neurology, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang 310012, P.R. China, Department of Massage, The Third Affiliated Hospital of Zhejiang Province Traditional Chinese Medical University, Hangzhou, Zhejiang 310012, P.R. China
Published online on: March 21, 2016 https://doi.org/10.3892/mmr.2016.5034
Pages: 4058-4064

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Parkinson's disease (PD) is the second most common progressive neurodegenerative movement disorder. Nicotinamide phosphoribosyltransferase (NAMPT) catalyzes the first rate‑limiting step in the nicotinamide adenine dinucleotide (NAD+) biosynthetic pathway in mammals, is a substrate for NAD+‑dependent enzymes, such as sirtuin 1 (SIRT1), and contributes to cell fate decisions. However, the role of NAMPT in PD has remained to be fully elucidated. In the present study, PC12 cells were treated with the neurotoxin 6-hydroxydopamine (6‑OHDA) to establish an in vitro model of PD, following which an obvious inhibitory effect on the levels of NAMPT and NAD+ as well as the NAD+/NADH ratio was detected. In addition, pre‑incubation with FK866, a highly specific NAMPT inhibitor, enhanced the inhibitory effects of 6‑OHDA on the viability of PC12, while pre‑incubation with nicotinamide mononucleotide (NMN), am enzymatic product of NAMPT, had the opposite effect. Furthermore, it was revealed that NMN markedly attenuated 6‑OHDA‑induced decreases in superoxide dismutase activity and glutathione levels, as well as 6‑OHDA‑induced increases in malondialdehyde and lactate dehydrogenase in PC12 cells. Furthermore, 6‑OHDA significantly reduced SIRT1 activity in PC12 cells, which was inhibited by NMN. The pharmacological activator resveratrol also significantly inhibited 6‑OHDA‑mediated decreases in PC12 cell viability while reversing 6‑OHDA‑induced decreases in SIRT1 levels. The results of the present study suggested that NMT protected against 6‑OHDA‑induced decreases in PC12 cell viability, and that SIRT1 activation had a role in this process. Treatment with NMN to activate SIRT1 may represent a novel therapeutic strategy for treating PD.

View Figures

View References

1	Beal MF: Experimental models of Parkinson's disease. Nat Rev Neurosci. 2:325–334. 2001. View Article : Google Scholar : PubMed/NCBI
2	Hanrott K, Gudmunsen L, O'Neill MJ and Wonnacott S: 6-hydroxydopamine-induced apoptosis is mediated via extracellular auto-oxidation and caspase 3-dependent activation of protein kinase Cdelta. J Biol Chem. 281:5373–5382. 2006. View Article : Google Scholar
3	Blandini F, Armentero MT and Martignoni E: The 6-hydroxy-dopamine model: News from the past. Parkinsonism Relat Disord. 14(Suppl 2): S124–S129. 2008. View Article : Google Scholar
4	Surendran S and Rajasankar S: Parkinson's disease: Oxidative stress and therapeutic approaches. Neurol Sci. 31:531–540. 2010. View Article : Google Scholar : PubMed/NCBI
5	Soto-Otero R, Méndez-Alvarez E, Hermida-Ameijeiras A, Muñoz-Patiño AM and Labandeira-Garcia JL: Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants. J Neurochem. 74:1605–1612. 2000. View Article : Google Scholar : PubMed/NCBI
6	Han XH, Cheng MN, Chen L, Fang H, Wang LJ, Li XT and Qu ZQ: 7,8-dihydroxyflavone protects PC12 cells against 6-hydroxydopamine-induced cell death through modulating PI3K/Akt and JNK pathways. Neurosci Lett. 581:85–88. 2014. View Article : Google Scholar : PubMed/NCBI
7	Xu DP, Zhang K, Zhang ZJ, Sun YW, Guo BJ, Wang YQ, Hoi PM, Han YF and Lee SM: A novel tetramethylpyrazine bisnitrone (TN-2) protects against 6-hydroxyldopamine-induced neurotoxicity via modulation of the NF-κB and the PKCα/PI3-K/Akt pathways. Neurochem Int. 78:76–85. 2014. View Article : Google Scholar : PubMed/NCBI
8	Wang L, Wang R, Jin M, Huang Y, Liu A, Qin J, Chen M, Wen S, Pi R and Shen W: Carvedilol attenuates 6-hydroxydo-pamine-induced cell death in PC12 Cells: Involvement of Akt and Nrf2/ARE pathways. Neurochem Res. 39:1733–1740. 2014. View Article : Google Scholar : PubMed/NCBI
9	Imai SI, Armstrong CM, Kaeberlein M and Guarente L: Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature. 403:795–800. 2000. View Article : Google Scholar : PubMed/NCBI
10	Rongvaux A, Shea RJ, Mulks MH, Gigot D, Urbain J, Leo O and Andris F: Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol. 32:3225–3234. 2002. View Article : Google Scholar
11	Revollo JR, Grimm AA and Imai S: The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals. Curr Opin Gastroenterol. 23:164–170. 2007. View Article : Google Scholar : PubMed/NCBI
12	Revollo JR, Grimm AA and Imai S: The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem. 279:50754–50763. 2004. View Article : Google Scholar : PubMed/NCBI
13	Ying W: NAD⁺/NADH and NADP+/NADPH in cellular functions and cell death: Regulation and biological consequences. Antioxid Redox Signal. 10:179–206. 2008. View Article : Google Scholar
14	Furukawa A, Tada-Oikawa S, Kawanishi S and Oikawa S: H₂O₂ accelerates cellular senescence by accumulation of acetylated p53 via decrease in the function of SIRT1 by NAD⁺ depletion. Cell Physiol Biochem. 20:45–54. 2007.
15	Lu L, Tang L, Wei W, Hong Y, Chen H, Ying W and Chen S: Nicotinamide mononucleotide improves energy activity and survival rate in an in vitro model of Parkinson's disease. Exp Ther Med. 8:943–950. 2014.PubMed/NCBI
16	Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ, Jin L, Boss O, Perni RB, Vu CB, et al: Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 450:712–716. 2007. View Article : Google Scholar : PubMed/NCBI
17	Araki T, Sasaki Y and Milbrandt J: Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science. 305:1010–1013. 2004. View Article : Google Scholar : PubMed/NCBI
18	Tanno M, Kuno A, Yano T, Miura T, Hisahara S, Ishikawa S, Shimamoto K and Horio Y: Induction of manganese superoxide dismutase by nuclear translocation and activation of SIRT1 promotes cell survival in chronic heart failure. J Biol Chem. 285:8375–8382. 2010. View Article : Google Scholar : PubMed/NCBI
19	Liu T, Liu PY and Marshall GM: The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res. 69:1702–1705. 2009. View Article : Google Scholar : PubMed/NCBI
20	Cohen HY, Miller C, Bitterman KJ, Wall NR, Hekking B, Kessler B, Howitz KT, Gorospe M, de Cabo R and Sinclair DA: Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science. 305:390–392. 2004. View Article : Google Scholar : PubMed/NCBI
21	Salminen A, Huuskonen J, Ojala J, Kauppinen A, Kaarniranta K and Suuronen T: Activation of innate immunity system during aging: NF-kB signaling is the molecular culprit of inflamm-aging. Ageing Res Rev. 7:83–105. 2008. View Article : Google Scholar
22	Chen WY, Wang DH, Yen RC, Luo J, Gu W and Baylin SB: Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell. 123:437–448. 2005. View Article : Google Scholar : PubMed/NCBI
23	Hasegawa K, Wakino S, Yoshioka K, Tatematsu S, Hara Y, Minakuchi H, Washida N, Tokuyama H, Hayashi K and Itoh H: Sirt1 protects against oxidative stress-induced renal tubular cell apoptosis by the bidirectional regulation of catalase expression. Biochem Biophys Res Commun. 372:51–56. 2008. View Article : Google Scholar : PubMed/NCBI
24	Jeong J, Juhn K, Lee H, Kim SH, Min BH, Lee KM, Cho MH, Park GH and Lee KH: SIRT1 promotes DNA repair activity and deacetylation of Ku70. Exp Mol Med. 39:8–13. 2007. View Article : Google Scholar : PubMed/NCBI
25	Bu Q, Yang Y, Yan G, Hu Z, Hu C, Duan J, Lv L, Zhou J, Zhao J, Shao X, et al: Proteomic analysis of the nucleus accumbens in rhesus monkeys of morphine dependence and withdrawal intervention. J Proteomics. 75:1330–1342. 2012. View Article : Google Scholar
26	Zhao X, Zhai S, An MS, Wang YH, Yang YF, Ge HQ, Liu JH and Pu XP: Neuroprotective effects of protocatechuic aldehyde against neurotoxin-induced cellular and animal models of Parkinson's disease. PloS One. 8:e782202013. View Article : Google Scholar : PubMed/NCBI
27	Blum D, Torch S, Lambeng N, Nissou M, Benabid AL, Sadoul R and Verna JM: Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: Contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol. 65:135–172. 2001. View Article : Google Scholar : PubMed/NCBI
28	Schober A: Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res. 318:215–224. 2004. View Article : Google Scholar : PubMed/NCBI
29	Saito Y, Nishio K, Ogawa Y, Kinumi T, Yoshida Y, Masuo Y and Niki E: Molecular mechanisms of 6-hydroxydopamine-induced cytotoxicity in PC12 cells: Involvement of hydrogen peroxide-dependent and-independent action. Free Radic Biol Med. 42:675–685. 2007. View Article : Google Scholar : PubMed/NCBI
30	Fujita H, Ogino T, Kobuchi H, Fujiwara T, Yano H, Akiyama J, Utsumi K and Sasaki J: Cell-permeable cAMP analog suppresses 6-hydroxydopamine-induced apoptosis in PC12 cells through the activation of the Akt pathway. Brain Res. 1113:10–23. 2006. View Article : Google Scholar : PubMed/NCBI
31	Yang T and Sauve AA: NAD metabolism and sirtuins: Metabolic regulation of protein deacetylation in stress and toxicity. AAPS J. 8:E632–E643. 2006. View Article : Google Scholar
32	Bürkle A: Poly (ADP-ribose). The most elaborate metabolite of NAD⁺. FEBS J. 272:4576–4589. 2005. View Article : Google Scholar
33	Halliwell B: Oxidative stress and neurodegeneration: Where are we now? J Neurochem. 97:1634–1658. 2006. View Article : Google Scholar : PubMed/NCBI
34	Zhang T and Kraus WL: SIRT1-dependent regulation of chromatin and transcription: Linking NAD metabolism and signaling to the control of cellular functions. Biochim Biophys Acta. 1804:1666–1675. 2010. View Article : Google Scholar :